ACADIA Pharmaceuticals Inc. $ACAD Stock Holdings Boosted by Walleye Capital LLC

Walleye Capital LLC grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 68.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 87,788 shares of the biopharmaceutical company’s stock after purchasing an additional 35,826 shares during the quarter. Walleye Capital LLC’s holdings in ACADIA Pharmaceuticals were worth $1,894,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of ACAD. Vanguard Group Inc. boosted its stake in ACADIA Pharmaceuticals by 9.0% during the first quarter. Vanguard Group Inc. now owns 15,203,234 shares of the biopharmaceutical company’s stock valued at $252,526,000 after buying an additional 1,255,594 shares in the last quarter. Geode Capital Management LLC raised its position in ACADIA Pharmaceuticals by 2.4% in the second quarter. Geode Capital Management LLC now owns 3,024,097 shares of the biopharmaceutical company’s stock worth $65,238,000 after acquiring an additional 69,584 shares in the last quarter. Fred Alger Management LLC lifted its holdings in ACADIA Pharmaceuticals by 2.0% in the 1st quarter. Fred Alger Management LLC now owns 2,769,828 shares of the biopharmaceutical company’s stock valued at $46,007,000 after acquiring an additional 54,899 shares during the last quarter. First Trust Advisors LP boosted its position in shares of ACADIA Pharmaceuticals by 2.8% during the 2nd quarter. First Trust Advisors LP now owns 2,434,376 shares of the biopharmaceutical company’s stock valued at $52,509,000 after purchasing an additional 65,914 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its position in shares of ACADIA Pharmaceuticals by 73.7% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 1,977,432 shares of the biopharmaceutical company’s stock valued at $32,845,000 after purchasing an additional 838,728 shares in the last quarter. Institutional investors and hedge funds own 96.71% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on ACAD. JPMorgan Chase & Co. dropped their target price on shares of ACADIA Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a report on Monday, November 17th. Wall Street Zen raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Citigroup initiated coverage on ACADIA Pharmaceuticals in a research report on Tuesday, October 21st. They set a “buy” rating and a $33.00 price objective for the company. Royal Bank Of Canada decreased their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating on the stock in a report on Thursday, November 6th. Finally, Cowen reaffirmed a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.89.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $26.76 on Tuesday. ACADIA Pharmaceuticals Inc. has a twelve month low of $13.40 and a twelve month high of $27.73. The stock has a market cap of $4.53 billion, a price-to-earnings ratio of 17.26, a PEG ratio of 7.37 and a beta of 0.67. The firm’s 50 day moving average price is $22.82 and its two-hundred day moving average price is $23.08.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.28. The company had revenue of $278.63 million during the quarter, compared to analyst estimates of $276.52 million. ACADIA Pharmaceuticals had a return on equity of 14.61% and a net margin of 24.94%.The company’s revenue for the quarter was up 11.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 earnings per share. On average, research analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.7 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director James M. Daly sold 30,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the completion of the sale, the director directly owned 4,041 shares of the company’s stock, valued at approximately $90,397.17. This represents a 88.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Mark C. Schneyer sold 10,262 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $23.69, for a total value of $243,106.78. Following the transaction, the executive vice president directly owned 53,338 shares in the company, valued at approximately $1,263,577.22. This trade represents a 16.14% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 47,844 shares of company stock valued at $1,093,684. Corporate insiders own 28.30% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.